Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 159 participants.

Also called NCT07423975

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 159 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07423975
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07423975. Randomized; single masking; primary purpose treatment. Start 2026-04-08 (actual); primary completion 2026-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke
Acronym
ARTS-SAFE
Condition
Stroke Acute
Condition
Endovascular Treatment
Intervention (Drug)
High-dose Anakinra
Intervention (Drug)
Low-dose Anakinra
Intervention (Other)
Standard medical treatment
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct07423975
Content hash
915d915aec460c2b8bae1e2fed2209651bc3cf5bd588335459d346b39919bf63